{"id":"lebrikizumab-pen","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Upper respiratory tract infections"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IL-4 and IL-13 are key cytokines driving type 2 inflammatory responses. By binding to IL-4Rα, lebrikizumab prevents both IL-4 and IL-13 from activating their downstream signaling pathways, thereby suppressing eosinophilic and allergic inflammation. This mechanism is particularly relevant in diseases characterized by elevated type 2 immune responses.","oneSentence":"Lebrikizumab is a monoclonal antibody that blocks interleukin-4 receptor alpha (IL-4Rα), inhibiting IL-4 and IL-13 signaling to reduce type 2 inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:34.980Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate-to-severe atopic dermatitis"},{"name":"Uncontrolled asthma with type 2 inflammation"}]},"trialDetails":[{"nctId":"NCT06444165","phase":"PHASE3","title":"Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2024-06-04","conditions":"Atopic Dermatitis","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Lebrikizumab Pen","genericName":"Lebrikizumab Pen","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lebrikizumab is a monoclonal antibody that blocks interleukin-4 receptor alpha (IL-4Rα), inhibiting IL-4 and IL-13 signaling to reduce type 2 inflammation. Used for Moderate-to-severe atopic dermatitis, Uncontrolled asthma with type 2 inflammation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}